Collplant biotechnologies provides business updates and second quarter 2022 financial results

Co-development of rhcollagen-based dermal and soft tissue fillers with abbvie is progressing company's 3d bioprinted regenerative breast implant program remains on track to conclude large animal study in q4 development of aseptic process for the production of sterile rhcollagen anticipated to be completed in q4 strong balance sheet with cash and cash equivalents of $36m as of june 30, 2022 rehovot, israel , aug. 25, 2022 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetic medicine company developing innovative human collagen-based technologies and products for tissue regeneration and organ manufacturing, today announced financial results for the second quarter ended june 30, 2022 and provided an update on the company's business developments. "i am very pleased with the company's execution and significant advances across our diverse and expanding product portfolio.
CLGN Ratings Summary
CLGN Quant Ranking